C4 Therapeutics to advance cemsidomide as best-in-class IKZF1/3 degrader. Phase 2 trial to begin Q1 2026 with recommended dose of 100 µg.

Source: Unusual Whales The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.